Identifying ways to activate adiponectin/AdipoR signaling is expected to pave the way for the development of definitive therapies for the metabolic syndrome, type 2 diabetes, and atherosclerosis. This evidence concerns the gene ADIPOQ and type 2 diabetes mellitus.